Dyadic Launches Animal-Origin-Free Recombinant DNase I
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy DYAI?
Dyadic Applied BioSolutions and Fermbox Bio announced the commercial launch of animal-origin-free Recombinant DNase I. This represents the first commercialized product under the companies expanded collaboration announced in 2025 and marks another step in Dyadic's accelerating transition from platform development to commercial product expansion and recurring revenue growth. Produced using Dyadic's proprietary high-yield fungal microbial expression platforms and Fermbox Bio's scale-up and biomanufacturing capabilities, Recombinant DNase I is currently available in research grade with a cGMP-grade version in development to support biopharmaceutical manufacturing and cell and gene therapy applications. Recombinant DNase I is an endonuclease enzyme used for nucleic-acid clean-up and sample preparation workflows where residual DNA can interfere with analytical results. Its RNase-free specification supports RNA integrity in sensitive RNA workflows across biological research, biotechnology, and molecular diagnostics. DNase I is a strategically important enzyme and the first in a planned series of recombinant enzymes and proteins expected to be commercially introduced throughout 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DYAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DYAI
About DYAI
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Dyadic and Fermbox Launch New Animal-Origin-Free Product
- Commercialization Milestone: The launch of Recombinant DNase I (RNase-free) by Dyadic and Fermbox marks the first commercial product following their expanded collaboration in 2025, showcasing Dyadic's accelerated transition from platform development to commercial product expansion, which is expected to drive recurring revenue growth.
- Technological Advantage: Produced using Dyadic's high-yield fungal microbial expression platforms and Fermbox's biomanufacturing capabilities, the product is currently available in research grade, with a cGMP-grade version in development to support biopharmaceutical manufacturing and cell and gene therapy applications.
- Market Demand Alignment: As a strategically important endonuclease enzyme, Recombinant DNase I is widely used in biological research and molecular diagnostics to effectively clean up residual DNA in samples, ensuring RNA integrity and meeting the market's demand for high-quality biological reagents.
- Future Product Pipeline: The collaboration plans to introduce a series of recombinant enzymes and proteins, including recombinant α-lactalbumin and recombinant human FGF-2, targeting high-demand areas such as cell culture media and vaccine manufacturing, further solidifying Dyadic's position in the biotechnology market.
See More
Dyadic and Inzymes Advance Non-Animal Chymosin Commercialization
- Commercialization Milestone: Dyadic and Inzymes announced the planned commercialization of recombinant non-animal chymosin in 2026, marking the successful completion of final development activities under their 2023 collaboration agreement, earning a $200,000 milestone payment and enhancing the market potential for non-animal dairy enzymes.
- Market Potential: The global dairy processing enzyme market is estimated to reach $1.5 to $2.0 billion annually, driven by increasing cheese consumption and rising demand for sustainable fermentation-derived alternatives, positioning Dyadic's non-animal chymosin to meet this market need.
- Significant Technical Advantage: Dyadic's microbial expression platforms enable efficient development and scalable manufacturing, and when combined with Inzymes' commercialization expertise, ensure that the non-animal chymosin meets evolving customer requirements for performance, consistency, and supply reliability, enhancing market competitiveness.
- Portfolio Expansion: As additional non-animal dairy enzyme candidates progress, the collaboration between Dyadic and Inzymes will further enrich their product portfolio in the fermentation-derived food enzyme market, supporting diversified growth across life sciences, food and nutrition, and industrial biotechnology sectors.
See More
Dyadic Launches AlbuFree™ DX Recombinant Human Albumin
- Product Launch: Dyadic and Proliant have launched AlbuFree™ DX recombinant human albumin, utilizing Dyadic's proprietary fungal expression technology, marking a significant advancement in Dyadic's commercialization strategy for recombinant protein products, which is expected to enhance the company's market share in the life sciences sector.
- Market Demand: The demand for recombinant human albumin is rising in cell culture and life science applications, and the introduction of AlbuFree™ DX not only meets the need for animal-free, scalable, and supply-secure inputs but also creates a recurring revenue stream for Dyadic.
- Collaborative Advantage: Proliant's extensive experience in global albumin production and distribution network will provide strong support for the market promotion of AlbuFree™ DX, ensuring product quality and reliability, thereby further solidifying Dyadic's market position.
- Future Outlook: Dyadic plans to continue advancing the development of additional recombinant proteins through a combination of internal programs and strategic partnerships, further expanding its product portfolio in life sciences, nutrition, and industrial applications, enhancing the company's long-term growth potential.
See More
HC Wainwright & Co. Initiates Coverage on Dyadic International with a Buy Rating and Sets Price Target at $3
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Dyadic and Fermbox Launch New Animal-Origin-Free Product
- Commercialization Milestone: The launch of Recombinant DNase I (RNase-free) by Dyadic and Fermbox marks the first commercial product following their expanded collaboration in 2025, showcasing Dyadic's accelerated transition from platform development to commercial product expansion, which is expected to drive recurring revenue growth.
- Technological Advantage: Produced using Dyadic's high-yield fungal microbial expression platforms and Fermbox's biomanufacturing capabilities, the product is currently available in research grade, with a cGMP-grade version in development to support biopharmaceutical manufacturing and cell and gene therapy applications.
- Market Demand Alignment: As a strategically important endonuclease enzyme, Recombinant DNase I is widely used in biological research and molecular diagnostics to effectively clean up residual DNA in samples, ensuring RNA integrity and meeting the market's demand for high-quality biological reagents.
- Future Product Pipeline: The collaboration plans to introduce a series of recombinant enzymes and proteins, including recombinant α-lactalbumin and recombinant human FGF-2, targeting high-demand areas such as cell culture media and vaccine manufacturing, further solidifying Dyadic's position in the biotechnology market.
See More
Dyadic and Inzymes Advance Non-Animal Chymosin Commercialization
- Commercialization Milestone: Dyadic and Inzymes announced the planned commercialization of recombinant non-animal chymosin in 2026, marking the successful completion of final development activities under their 2023 collaboration agreement, earning a $200,000 milestone payment and enhancing the market potential for non-animal dairy enzymes.
- Market Potential: The global dairy processing enzyme market is estimated to reach $1.5 to $2.0 billion annually, driven by increasing cheese consumption and rising demand for sustainable fermentation-derived alternatives, positioning Dyadic's non-animal chymosin to meet this market need.
- Significant Technical Advantage: Dyadic's microbial expression platforms enable efficient development and scalable manufacturing, and when combined with Inzymes' commercialization expertise, ensure that the non-animal chymosin meets evolving customer requirements for performance, consistency, and supply reliability, enhancing market competitiveness.
- Portfolio Expansion: As additional non-animal dairy enzyme candidates progress, the collaboration between Dyadic and Inzymes will further enrich their product portfolio in the fermentation-derived food enzyme market, supporting diversified growth across life sciences, food and nutrition, and industrial biotechnology sectors.
See More
Dyadic Launches AlbuFree™ DX Recombinant Human Albumin
- Product Launch: Dyadic and Proliant have launched AlbuFree™ DX recombinant human albumin, utilizing Dyadic's proprietary fungal expression technology, marking a significant advancement in Dyadic's commercialization strategy for recombinant protein products, which is expected to enhance the company's market share in the life sciences sector.
- Market Demand: The demand for recombinant human albumin is rising in cell culture and life science applications, and the introduction of AlbuFree™ DX not only meets the need for animal-free, scalable, and supply-secure inputs but also creates a recurring revenue stream for Dyadic.
- Collaborative Advantage: Proliant's extensive experience in global albumin production and distribution network will provide strong support for the market promotion of AlbuFree™ DX, ensuring product quality and reliability, thereby further solidifying Dyadic's market position.
- Future Outlook: Dyadic plans to continue advancing the development of additional recombinant proteins through a combination of internal programs and strategic partnerships, further expanding its product portfolio in life sciences, nutrition, and industrial applications, enhancing the company's long-term growth potential.
See More
HC Wainwright & Co. Initiates Coverage on Dyadic International with a Buy Rating and Sets Price Target at $3
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
See More
